| Literature DB >> 31098725 |
Anna Delamarre1,2,3, François Tison1,2,3, Qin Li4,5, Monique Galitzky6, Olivier Rascol6,7,8, Erwan Bezard1,2,3,4,5, Wassilios G Meissner9,10,11,12,13.
Abstract
We tested in a translational approach the usefulness of plasma creatine kinase (CK) as an objective biomarker for levodopa-induced dyskinesia (LID). Plasma CK levels were measured in five dyskinetic parkinsonian non-human primates (NHP) and in ten PD patients with LID who participated in a treatment trial with simvastatin. Plasma CK levels were increased in dyskinetic NHP and correlated with LID severity while they were not affected by LID severity in PD patients.Entities:
Keywords: Biomarker; Creatine kinase; Levodopa-induced dyskinesia; Parkinson’s disease
Year: 2019 PMID： 31098725 DOI： 10.1007/s00702-019-02015-x
Source DB: PubMed Journal: J Neural Transm (Vienna) ISSN： 0300-9564 Impact factor: 3.575